Aevi Genomic Medicine Company

Aevi Genomic Medicine was founded as Medgenics in 2000 in Israel. Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies. The company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia. The company tests non-stimulant glutamatergic neuromodulator in subjects with ADHD, as a potential treatment for a sub-population of ADHD patients with genetic mutations that disrupt the mGluR network.
Technology: Biopharma, Biotechnology, Health Care, Life Science
Industry: Personalized Medicine
Headquarters: Wayne, Pennsylvania, United States
Founded Date: 2000
Employees Number: 11-50
Funding Status: IPO

Visit Website
Register and Claim Ownership